SCHEMBL860023

SCHEMBL860023

N#CCc1c(CBr)ccc2ccccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.38
SRC P12931 1/20 0.38
HSD17B10 Q99714 3/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALDH1A1 P00352 4/20 0.37
TDP1 Q9NUW8 4/20 0.37
CYP2A6 P11509 1/20 0.37
TSHR P16473 1/20 0.37
KDM4E B2RXH2 5/20 0.36
GAA P10253 3/20 0.36
MAPT P10636 3/20 0.36
TAAR1 Q96RJ0 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
HPRT1 P00492 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
ANPEP P15144 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8974659 0.87 HSD17B10 (0.41) EGFRSRCHSD17B10CYP1A2CYP2C9
SCHEMBL11940533 0.83 L3MBTL1 (0.44) EGFRSRCHSD17B10CYP1A2CYP2C9
SCHEMBL235416 0.81 ALDH1A1 (0.46) HSD17B10CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL7463076 0.77 HSD17B10 (0.46) HSD17B10CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL6173898 0.75 TSHR (0.48) EGFRSRCHSD17B10CYP1A2CYP2C9
SCHEMBL4594281 0.75 ANPEP (0.48) HSD17B10CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL953654 0.75 HSD17B10 (0.63) HSD17B10CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL30439535 0.75 ANPEP (0.48) HSD17B10CYP1A2CYP2C19ALDH1A1TDP1
SCHEMBL956020 0.75 POLB (0.46) HSD17B10ALDH1A1TDP1CYP2A6TSHR
SCHEMBL11940549 0.74 HTT (0.56) HSD17B10CYP1A2CYP2C19ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US disclosed
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US disclosed
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US disclosed
US-9340491-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2016-05-17 US disclosed
US-9340491-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2016-05-17 US disclosed
US-9340491-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2016-05-17 US disclosed
CN-102438612-B Nitrile derivatives, their pharmaceutical use and compositions CELLCEUTIX CORP. (US) 2016-02-03 CN disclosed
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US disclosed
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US disclosed
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US disclosed
US-8338454-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2012-12-25 US disclosed
US-8338454-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2012-12-25 US disclosed
US-8338454-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2012-12-25 US disclosed
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION 2012-07-26 US disclosed
CN-102438612-A Nitrile derivatives, their pharmaceutical use and compositions CELLCEUTIX CORP 2012-05-02 CN disclosed
EP-2432464-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS Cellceutix Corporation (US) 2012-03-28 EP disclosed
WO-2010135170-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 WO disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 EGFR 1039/4885SRC 1161/4885HSD17B10 2190/4885
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 EGFR 1039/4885SRC 1161/4885HSD17B10 2190/4885
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 EGFR 1039/4885SRC 1161/4885HSD17B10 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.